Development
Cytokinetics, Incorporated
CYTK
$36.16
-$0.42-1.15%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 342.33% | -56.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 342.33% | -56.40% | |||
| Cost of Revenue | 2.96% | -0.80% | |||
| Gross Profit | -1.40% | 0.21% | |||
| SG&A Expenses | 9.98% | 0.98% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.26% | -0.22% | |||
| Operating Income | -4.21% | -0.18% | |||
| Income Before Tax | -5.77% | -0.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.77% | -0.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.77% | -0.61% | |||
| EBIT | -4.21% | -0.18% | |||
| EBITDA | -0.56% | -0.18% | |||
| EPS Basic | -2.58% | -0.28% | |||
| Normalized Basic EPS | -2.58% | -0.29% | |||
| EPS Diluted | -2.58% | -0.28% | |||
| Normalized Diluted EPS | -2.58% | -0.29% | |||
| Average Basic Shares Outstanding | 3.12% | 0.33% | |||
| Average Diluted Shares Outstanding | 3.12% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||